Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

86.37USD
19 Sep 2017
Change (% chg)

$1.05 (+1.23%)
Prev Close
$85.32
Open
$85.54
Day's High
$86.66
Day's Low
$85.38
Volume
7,786,420
Avg. Vol
6,015,258
52-wk High
$89.69
52-wk Low
$55.06

Latest Key Developments (Source: Significant Developments)

AbbVie announces positive topline results from phase 3 trial evaluating Venclexta/Venclyxto tablets in combination with Rituxan
Monday, 18 Sep 2017 11:30am EDT 

Sept 18 (Reuters) - AbbVie Inc ::AbbVie announces positive topline results from phase 3 trial evaluating Venclexta™/Venclyxto™ (Venetoclax) tablets in combination with Rituxan® (Rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic Leukemia.Abbvie Inc - ‍Phase 3 Murano Study Of Venclexta venclyxto tablets in combination with rituxan met its primary endpoint​.Abbvie inc - ‍Venclexta/Venclyxto is being developed by AbbVie and Roche​.AbbVie Inc - ‍Safety data, including serious and most common adverse events and discontinuation rates, are currently being analyzed​.AbbVie - ‍Tumor lysis syndrome, including fatal events, has occurred in patients with previously treated CLL with high tumor burden on treating with Venclyxto​.  Full Article

AbbVie's upadacitinib meets all primary and ranked secondary endpoints
Monday, 11 Sep 2017 08:02am EDT 

Sept 11 (Reuters) - AbbVie Inc ::AbbVie's upadacitinib (ABT-494) meets all primary and ranked secondary endpoints in second phase 3 study in rheumatoid arthritis.AbbVie Inc - ‍safety profile of upadacitinib was consistent with previously reported studies, with no new safety signals detected​.AbbVie - ‍Select-beyond showed positive results with both doses (15 mg, 30 mg once-daily) meeting primary endpoints in difficult-to-treat patient population​.AbbVie Inc - ‍phase 3 trials of upadacitinib in psoriatic arthritis are ongoing​.  Full Article

Abbvie Inc says sets quarterly cash dividend of $0.64/shr
Friday, 8 Sep 2017 11:03am EDT 

Sept 8 (Reuters) - Abbvie Inc :Says ‍board of directors of Abbvie Inc declared a quarterly cash dividend of $0.64 per share​.Says Since 2013, Abbvie has increased its dividend by 60 percent .  Full Article

Coherus Biosciences says ‍PTAB denied 4 petitions for inter partes review of Abbvie's patent
Thursday, 7 Sep 2017 11:57am EDT 

Sept 7 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences provides update on ‘619 IPR institution decision.Says ‍PTAB denied institution of all 4 petitions for inter partes review of Abbvie's patent related to Abbvie's Humira formulation​.  Full Article

Abbvie's upadacitinib meets primary endpoint in phase 2b study in atopic dermatitis
Thursday, 7 Sep 2017 08:03am EDT 

Sept 7 (Reuters) - Abbvie Inc :Abbvie's upadacitinib (abt-494) meets primary endpoint in phase 2b study in atopic dermatitis.Abbvie Inc - "‍look forward to advancing upadacitinib to phase 3 studies in 2018"​.Abbvie Inc - ‍upadacitinib is not approved by regulatory authorities and safety and efficacy have not been established​.Abbvie-‍results showed that primary, secondary endpoints, patients treated with upadacitinib achieved improvements that were statistically significant.Abbvie Inc - ‍in study, no new safety signals were detected​.  Full Article

Abbvie submits NDA to U.S. FDA for investigational oral treatment Elagolix for management of endometriosis with associated pain
Wednesday, 6 Sep 2017 08:01am EDT 

Sept 6 (Reuters) - Abbvie Inc ::Abbvie submits new drug application to U.S. FDA for investigational oral treatment Elagolix for the management of endometriosis with associated pain.Abbvie Inc - ‍submitted NDA to U.S. Food and drug administration for Elagolix​.  Full Article

Inventiva and AbbVie extend agreement
Monday, 4 Sep 2017 01:31am EDT 

Sept 4 (Reuters) - INVENTIVA SA ::INVENTIVA AND ABBVIE EXTEND AGREEMENT TO DISCOVER NEW POTENT ORALLY-AVAILABLE SMALL MOLECULE RORΓ INVERSE AGONIST DRUG CANDIDATES.INVENTIVA WILL RECEIVE AN UNDISCLOSED RESEARCH PAYMENT‍​.INVENTIVA WILL RECEIVE MILESTONE PAYMENTS WHEN A NEW CANDIDATE IS IDENTIFIED‍​.INVENTIVA WILL ALSO BE ELIGIBLE FOR DEVELOPMENT AND SALES MILESTONES AS WELL AS ROYALTIES ON SALES‍​.  Full Article

Abbvie says HUMIRA will now be reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland, Labrador, Saskatchewan, Yukon
Tuesday, 29 Aug 2017 08:00am EDT 

Aug 29 (Reuters) - Abbvie Inc ::Abbvie Inc - HUMIRA will now be reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland and Labrador, Saskatchewan and Yukon.Abbvie Inc - HUMIRA is also now covered by federal non-insured health benefits program.  Full Article

U.S. FDA says approved Abbvie's Mavyret for Hepatitis C
Thursday, 3 Aug 2017 03:22pm EDT 

Aug 3 (Reuters) - U.S. Food and Drug Administration ::FDA approves Mavyret for Hepatitis C ‍​.U.S. FDA- FDA granted the application priority review, breakthrough therapy designations, granted approval of Mavyret to Abbvie Inc ‍​.  Full Article

U.S. FDA expands approval of Imbruvica for treatment of adult patients with cGVHD
Wednesday, 2 Aug 2017 11:39am EDT 

Aug 2 (Reuters) - U.S. Food and Drug Administration::Expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease.Says granted the approval of Imbruvica to Pharmacyclics LLC.  Full Article

FTC clears hurdle in antitrust case against Abbvie over 'pay for delay' deal

The Federal Trade Commission on Friday cleared a major hurdle in its civil antitrust case alleging Abbvie Inc used frivolous lawsuits to block generic versions of its testosterone gel AndroGel from getting to market.